SEC Filing Summary: Tempur-Pedic International Inc. (10-Q)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2004, for Tempur-Pedic International Inc. (TPX). The Company is a vertically-integrated manufacturer and distributor of premium visco-elastic foam mattresses and pillows, operating in 60 countries. The business is divided into two reportable segments: Domestic (U.S. manufacturing and sales) and International (Denmark manufacturing and global distribution). The Company completed its Initial Public Offering (IPO) in December 2003.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2004 |
Six Months Ended June 30, 2004 |
|---|---|---|
| Net Sales | $151.6 million | $304.7 million |
| Gross Profit | $80.8 million (53% margin) | $162.2 million (53% margin) |
| Operating Income | $33.0 million (22% margin) | $63.5 million (21% margin) |
| Net Income | $16.9 million | $28.7 million |
| Diluted EPS | $0.16 | $0.28 |
| Cash from Operations | N/A | $29.7 million |
| Total Debt (Book Value) | $311.5 million | |
| Working Capital | $81.2 million | |
| Cash & Equivalents | $25.1 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 33% ($37.9 million) for the quarter and 39% ($85.9 million) for the six months compared to the same periods in 2003. Growth was driven primarily by the Retail channel in the Domestic segment (71% of Q2 growth) and International Retail channel (28% of Q2 growth).
- Margin Compression: Operating income margin decreased from 24% to 22% (Q2) and 23% to 21% (YTD). This was attributed to a shift in sales mix toward the Retail channel (wholesale pricing vs. direct MSRP), increased IT spending, and Sarbanes-Oxley implementation costs.
- Debt Reduction: In January 2004, the Company redeemed $52.5 million of Senior Subordinated Notes using IPO proceeds, resulting in a $5.4 million loss on extinguishment of debt recorded in the first half of 2004.
- Stock-Based Compensation: The Company recorded $3.0 million in stock-based compensation expense for the six months ended June 30, 2004, related to options granted prior to the IPO.
Guidance, Outlook, and Risks
- Capital Expenditures: The Company expects 2004 capital expenditures to be approximately $28.0 million, with $16.0 million allocated to expanding the European manufacturing facility.
- Liquidity: The Company maintains approximately $26.5 million in unused availability under its revolving credit facilities. Management intends to retain earnings to fund growth and does not anticipate paying dividends in the foreseeable future.
- Key Risks:
- Competition: Intense competition in the mattress industry, including potential price wars and new entrants offering similar foam products.
- Customer Concentration: The top five customers accounted for 13% of Q2 sales and 14% of YTD sales.
- Regulatory: Potential costs associated with new fire retardancy standards (e.g., California standards effective Jan 2005) and antitrust investigations regarding pricing.
- Supply Chain: Reliance on two primary suppliers for polyol (a key raw material) and concentration of manufacturing in only two facilities (Denmark and Virginia).
- Warranty & Returns: Risks related to the adequacy of warranty reserves and potential increases in return rates as sales volume expands.
Investor Verification Checklist
- Verify the sustainability of the 8% return rate in the U.S. as sales volume increases.
- Monitor the impact of the Retail channel mix on gross margins, as wholesale pricing is lower than direct sales.
- Assess the timeline and cost implications of the European manufacturing expansion ($16 million expected in 2004).
- Review the status of antitrust investigations regarding mattress industry pricing practices.
- Confirm the adequacy of warranty reserves ($3.6 million as of June 30, 2004) given the long-term nature of mattress warranties (15-20 years).
- Track the interest rate exposure on the $212 million of variable rate debt, noting the $60 million interest rate cap protection.